{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-24-000049","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.630417+00:00","generated_at":"2026-05-31T20:48:00.937823+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LENZ Therapeutics raises $30M from Ridgeback Capital in PIPE at $19/share","bullets":["PIPE financing of $30M with Ridgeback Capital at $19.00 per share; expected to close July 17, 2024.","Proceeds to support regulatory and commercial launch activities for LNZ100, a presbyopia eye drop.","NDA submission for LNZ100 planned mid-2024; Phase 3 CLARITY data cited as strong.","Ridgeback Capital founder Dr. Wayne Holman expressed support; shares unregistered with resale registration to be filed.","Existing cash plus PIPE proceeds to fund pre-commercial and potential launch activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-24-000049","json":"https://secwatch.observer/filing/0001815776-24-000049.json","markdown":"https://secwatch.observer/filing/0001815776-24-000049.md","text":"https://secwatch.observer/filing/0001815776-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000049/0001815776-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000049/lenz-20240714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:48:00.937823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}